Lortalamine

Lortalamine is a tricyclic antidepressant that was developed in the 1980s for the treatment of depression. It acts primarily as a selective norepinephrine reuptake inhibitor (NRI), increasing levels of norepinephrine in the brain by inhibiting its reabsorption into nerve cells. Lortalamine was investigated for use in major depressive disorder but was never marketed, reportedly due to concerns about ocular toxicity observed during preclinical or clinical studies. The drug is structurally related to other tricyclic antidepressants but is distinguished by its selectivity for norepinephrine over serotonin or dopamine transporters.